Annexon, Inc.
NASDAQ:ANNX
Overview | Financials
Company Name | Annexon, Inc. |
Symbol | ANNX |
Currency | USD |
Price | 6.61 |
Market Cap | 698,372,940 |
Dividend Yield | 0% |
52-week-range | 2.27 - 8.4 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Douglas Love Esq., J.D. |
Website | https://www.annexonbio.com |
An error occurred while fetching data.
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD